PharmaNutra S.p.A. (BIT:PHN), an Italian company specialising in mineral-based nutritional supplements and medical devices for muscles and joints, announced on Wednesday that it has signed an agreement with a strategy consulting company to define the development plan for its US subsidiary.
PharmaNutra USA Corp, based in Florida, distributes and markets PharmaNutra's products in the United States.
Following a recent market analysis, the US consulting firm will work over two months to draft a growth plan in partnership with PharmaNutra. The aim is to enhance business development in the US market, where PharmaNutra has received numerous patents and scientific recognitions from the medical community in recent years.
Roberto Lacorte, PharmaNutra S.p.A. CEO, said: "The design of this plan marks a significant advancement for PharmaNutra USA's business, a project we strongly support. We are pleased to partner with a leading consulting firm that has confirmed the growth drivers identified by PharmaNutra S.p.A. and the substantial potential of the American market for our product range."
ColdVentures partners with Medco Sports Medicine to combat heat stroke
Median Technologies secures funding for eyonis Lung Cancer Screening software
MicroAire Surgical Instruments acquires NEOSYAD
UCB launches 320 mg/2 mL single-injection administration option for BIMZELX (bimekizumab-bkzx) in US
Concept Medical reports first patient enrolled in MagicTouch SCB trial in peripheral artery disease
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Revvity and Element Biosciences partner to enhance neonatal sequencing for IVD testing
Implantica publishes real-world data supporting RefluxStop efficacy
Abingdon Health subsidiary awarded GBP500,000 contract
NanoVibronix completes pilot phase of UroShield study at University of Michigan
Hologic acquires Gynesonics for USD350m
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Microtech commences human clinical trial of microsensor platform for heart failure
Humacyte Global receives approval from FDA for Symvess
Defense Diagnostics launches DEFENT ONE All-In-One Fentanyl Detection Device in US